Phase II study of biweekly cetuximab plus mFOLFOX6 or mFOLFIRI as second-line treatment for metastatic colorectal cancer and exploratory analysis of associations between DNA methylation status and the efficacy of the anti-EGFR antibody: T-CORE1201.

J Gastrointest Oncol · 2023 · PMC10186538 · PMID 37201044

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

extremely significantno p-value reported

The role of anti-epidermal growth factor receptor (EGFR) therapies in chemotherapy for mCRC is extremely significant.

also in 7,787 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.